L. Bms and R. M. Novartis, Avril is a consultant/advisory board member for steering committee for trial MO25743: Vemurafenib in Brain Metastasis of Melanoma Patients

A. Frazao, M. Colombo, F. Bouquet, A. Toubert, A. A. Frazao et al., Caignard Development of methodology: A. Frazao Avril Acquisition of data (provided animals, acquired and managed patients, provided facilities Avril Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A Avril Writing, review, and/or revision of the manuscript, technical, or material support (i.e., reporting or organizing data, constructing databases): H. Benlalam Study supervision: A. Caignard Other, pp.949-54, 2002.

L. Tentori, P. Lacal, and G. Graziani, Challenging resistance mechanisms to therapies for metastatic melanoma, Trends in Pharmacological Sciences, vol.34, issue.12, pp.656-66, 2013.
DOI : 10.1016/j.tips.2013.10.003

P. Lito, N. Rosen, and D. Solit, Tumor adaptation and resistance to RAF inhibitors, Nature Medicine, vol.31, issue.11, pp.1401-1410, 2013.
DOI : 10.1038/nature11814

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011.
DOI : 10.1056/NEJMoa1103782

G. Fregni, M. Messaoudene, E. Fourmentraux-neves, S. Mazouz-dorval, J. Chanal et al., Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages, PLoS ONE, vol.363, issue.10, p.76928, 2013.
DOI : 10.1371/journal.pone.0076928.s003

URL : https://hal.archives-ouvertes.fr/hal-01619167

G. Fregni, A. Perier, G. Pittari, S. Jacobelli, X. Sastre et al., Unique Functional Status of Natural Killer Cells in Metastatic Stage IV Melanoma Patients and Its Modulation by Chemotherapy, Clinical Cancer Research, vol.17, issue.9, pp.2628-2665, 2011.
DOI : 10.1158/1078-0432.CCR-10-2084

R. Mocikat, H. Braumuller, A. Gumy, O. Egeter, H. Ziegler et al., Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses, Immunity, vol.19, issue.4, pp.561-570, 2003.
DOI : 10.1016/S1074-7613(03)00264-4

URL : https://doi.org/10.1016/s1074-7613(03)00264-4

L. Moretta and A. Moretta, Unravelling natural killer cell function: triggering and inhibitory human NK receptors, The EMBO Journal, vol.23, issue.2, pp.255-264, 2004.
DOI : 10.1038/sj.emboj.7600019

URL : http://emboj.embopress.org/content/embojnl/23/2/255.full.pdf

Y. Bryceson, M. March, H. Ljunggren, and E. Long, Activation, coactivation, and costimulation of resting human natural killer cells, Immunological Reviews, vol.137, issue.1, pp.73-91, 2006.
DOI : 10.1158/0008-5472.CAN-05-4603

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845883/pdf

T. Lakshmikanth, S. Burke, T. Ali, S. Kimpfler, F. Ursini et al., NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo, Journal of Clinical Investigation, vol.119, issue.5, pp.1251-63, 2009.
DOI : 10.1172/JCI36022DS1

M. Lopez-botet, M. Mc, T. Tb, J. Perez-villar, M. Llano et al., The CD94/ NKG2 C-type lectin receptor complex, Curr Top Microbiol Immunol, vol.230, pp.41-52, 1998.

M. Kornstein, R. Stewart, and D. Elder, Natural killer cells in the host response to melanoma, Cancer Res, vol.47, pp.1411-1413, 1987.

J. Schleypen, N. Baur, R. Kammerer, P. Nelson, K. Rohrmann et al., Cytotoxic Markers and Frequency Predict Functional Capacity of Natural Killer Cells Infiltrating Renal Cell Carcinoma, Clinical Cancer Research, vol.12, issue.3, pp.718-743, 2006.
DOI : 10.1158/1078-0432.CCR-05-0857

URL : http://clincancerres.aacrjournals.org/content/clincanres/12/3/718.full.pdf

A. Paschen, J. Baingo, and D. Schadendorf, Expression of stress ligands of the immunoreceptor NKG2D in melanoma: Regulation and clinical significance, European Journal of Cell Biology, vol.93, issue.1-2, pp.49-54, 2014.
DOI : 10.1016/j.ejcb.2014.01.009

N. Aptsiauri, T. Cabrera, R. Mendez, A. Garcia-lora, F. Ruiz-cabello et al., Role of Altered Expression of HLA Class I Molecules in Cancer Progression
DOI : 10.1007/978-0-387-72005-0_13

M. Allard, R. Oger, V. Vignard, J. Percier, G. Fregni et al., Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer, PLoS ONE, vol.87, issue.1, p.21118, 2011.
DOI : 10.1371/journal.pone.0021118.t002

URL : https://hal.archives-ouvertes.fr/inserm-01234644

L. Derre, M. Corvaisier, B. Charreau, A. Moreau, E. Godefroy et al., Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells, The Journal of Immunology, vol.177, issue.5, pp.3100-3107, 2006.
DOI : 10.4049/jimmunol.177.5.3100

E. Tremante, A. Ginebri, L. Monaco, E. Benassi, B. Frascione et al., A melanoma immune response signature including Human Leukocyte Antigen-E, Pigment Cell & Melanoma Research, vol.469, issue.1, pp.103-115, 2014.
DOI : 10.1038/nature09666

T. Arnon, H. Achdout, O. Levi, G. Markel, N. Saleh et al., Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus, Nature Immunology, vol.70, issue.5, pp.515-538, 2005.
DOI : 10.1021/bi020117v

V. Simhadri, K. Reiners, H. Hansen, D. Topolar, V. Simhadri et al., Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function, PLoS ONE, vol.26, issue.10, p.3377, 2008.
DOI : 10.1371/journal.pone.0003377.g004

URL : https://doi.org/10.1371/journal.pone.0003377

C. Brandt, M. Baratin, E. Yi, J. Kennedy, Z. Gao et al., The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans, The Journal of Experimental Medicine, vol.163, issue.7, pp.1495-503, 2009.
DOI : 10.1038/nri2326

T. Kaifu, B. Escaliere, L. Gastinel, E. Vivier, and M. Baratin, B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors, Cellular and Molecular Life Sciences, vol.282, issue.Suppl 9, pp.3531-3540, 2011.
DOI : 10.1074/jbc.M702504200

URL : https://hal.archives-ouvertes.fr/hal-00667776

G. Cao, J. Wang, X. Zheng, H. Wei, Z. Tian et al., Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6, Journal of Biological Chemistry, vol.22, issue.50, pp.29964-73, 2015.
DOI : 10.1182/blood-2013-02-482513

URL : http://www.jbc.org/content/290/50/29964.full.pdf

D. Beck, H. Niessner, K. Smalley, K. Flaherty, K. Paraiso et al., Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells, Science Signaling, vol.6, issue.8, p.7, 2013.
DOI : 10.1371/journal.pone.0023429

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698985/pdf

P. Vantourout, C. Willcox, A. Turner, C. Swanson, Y. Haque et al., Immunological Visibility: Posttranscriptional Regulation of Human NKG2D Ligands by the EGF Receptor Pathway, Science Translational Medicine, vol.8, issue.1, pp.231-280, 2014.
DOI : 10.1093/biostatistics/kxj037

X. Wu, Y. Tao, J. Hou, X. Meng, and J. Shi, Valproic Acid Upregulates NKG2D Ligand Expression through an ERK-dependent Mechanism and Potentially Enhances NK Cell-mediated Lysis of Myeloma, Neoplasia, vol.14, issue.12, pp.1178-89, 2012.
DOI : 10.1593/neo.121236

M. Borchers, N. Harris, S. Wesselkamper, M. Vitucci, and D. Cosman, NKG2D ligands are expressed on stressed human airway epithelial cells, AJP: Lung Cellular and Molecular Physiology, vol.291, issue.2, pp.222-253, 2006.
DOI : 10.1152/ajplung.00327.2005

URL : http://ajplung.physiology.org/content/ajplung/291/2/L222.full.pdf

H. Ogbomo, M. Michaelis, D. Klassert, H. Doerr, J. Cinatl et al., Resistance to Cytarabine Induces the Up-regulation of NKG2D Ligands and Enhances Natural Killer Cell Lysis of Leukemic Cells, Neoplasia, vol.10, issue.12, pp.1402-1412, 2008.
DOI : 10.1593/neo.08972

G. Chitadze, M. Lettau, S. Luecke, T. Wang, O. Janssen et al., NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human ???? T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors, OncoImmunology, vol.146, issue.4, p.1093276, 2016.
DOI : 10.1128/CDLI.8.6.1131???1135.2001

E. Schlecker, N. Fiegler, A. Arnold, P. Altevogt, R. et al., Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor NKp30, Cancer Research, vol.74, issue.13, pp.3429-3469, 2014.
DOI : 10.1158/0008-5472.CAN-13-3017

E. Diaz-rodriguez, J. Montero, A. Esparis-ogando, L. Yuste, and A. Pandiella, Extracellular Signal-regulated Kinase Phosphorylates Tumor Necrosis Factor ??-converting Enzyme at Threonine 735: A Potential Role in Regulated Shedding, Molecular Biology of the Cell, vol.269, issue.6, pp.2031-2075, 2002.
DOI : 10.1074/jbc.271.31.18989

S. Soond, B. Everson, D. Riches, and G. Murphy, ERK-mediated phosphorylation of Thr735 in TNF??-converting enzyme and its potential role in TACE protein trafficking, Journal of Cell Science, vol.118, issue.11, pp.2371-80, 2005.
DOI : 10.1242/jcs.02357

B. Sapkota, C. Hill, and B. Pollack, homozygous melanoma cells, OncoImmunology, vol.48, issue.1, p.22890, 2013.
DOI : 10.1158/1535-7163.MCT-06-0728

R. Sottile, P. Pangigadde, T. Tan, A. Anichini, F. Sabbatino et al., HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors, European Journal of Immunology, vol.80, issue.2, pp.409-428, 2016.
DOI : 10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A

L. Ruggeri, E. Urbani, P. Andre, A. Mancusi, A. Tosti et al., Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells, Haematologica, vol.101, issue.5, pp.626-659, 2016.
DOI : 10.3324/haematol.2015.135301

F. Romagne, P. Andre, P. Spee, S. Zahn, N. Anfossi et al., Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells, Blood, vol.114, issue.13, pp.2667-77, 2009.
DOI : 10.1182/blood-2009-02-206532

URL : https://hal.archives-ouvertes.fr/hal-00431858

B. Comin-anduix, T. Chodon, H. Sazegar, D. Matsunaga, S. Mock et al., The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations, Clinical Cancer Research, vol.16, issue.24, pp.6040-6048, 2010.
DOI : 10.1158/1078-0432.CCR-10-1911

B. Schilling, W. Sondermann, F. Zhao, K. Griewank, E. Livingstone et al., Differential influence of vemurafenib and dabrafenib on patients??? lymphocytes despite similar clinical efficacy in melanoma, Annals of Oncology, vol.25, issue.3, pp.747-53, 2014.
DOI : 10.1093/annonc/mdt587

L. De-andrade, M. Smyth, and L. Martinet, DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins, Immunology and Cell Biology, vol.172, issue.3, pp.237-281, 2014.
DOI : 10.1056/NEJMoa1104621

Z. Eroglu and A. Ribas, Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy, Therapeutic Advances in Medical Oncology, vol.33, issue.1, pp.48-56, 2016.
DOI : 10.1158/1078-0432.CCR-11-2479

C. Manzini, R. Vene, I. Cossu, M. Gualco, S. Zupo et al., Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function, Oncotarget, vol.7, issue.38, pp.60858-71, 2016.
DOI : 10.18632/oncotarget.11504

A. Chretien, L. Roy, A. Vey, N. Prebet, T. Blaise et al., Cancerinduced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity, Front Immunol, vol.5, p.122, 2014.

A. Boni, A. Cogdill, P. Dang, D. Udayakumar, C. Njauw et al., Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function, Cancer Research, vol.70, issue.13, pp.5213-5222, 2010.
DOI : 10.1158/0008-5472.CAN-10-0118

URL : http://cancerres.aacrjournals.org/content/canres/70/13/5213.full.pdf

L. Ferrari-de-andrade, S. Ngiow, K. Stannard, S. Rusakiewicz, M. Kalimutho et al., Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma, Cancer Research, vol.74, issue.24, pp.7298-308, 2014.
DOI : 10.1158/0008-5472.CAN-14-1339

P. Ebert, J. Cheung, Y. Yang, E. Mcnamara, R. Hong et al., MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade, Immunity, vol.44, issue.3, pp.609-630, 2016.
DOI : 10.1016/j.immuni.2016.01.024

URL : https://doi.org/10.1016/j.immuni.2016.01.024

A. Hooijkaas, J. Gadiot, M. Morrow, R. Stewart, T. Schumacher et al., Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma, OncoImmunology, vol.1, issue.5, pp.609-626, 2012.
DOI : 10.1002/cncr.25747

S. Murray and A. Lundqvist, Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience, Human Vaccines & Immunotherapeutics, vol.9, issue.3, pp.607-618, 2016.
DOI : 10.1016/j.intimp.2013.06.003

G. Navarro, A. Bjorklund, A. Chekenya, and M. , Therapeutic potential and challenges of natural killer cells in treatment of solid tumors, Front Immunol, vol.29, pp.202-209, 2015.